Dr Michael Koren, Jacksonville Center for Clinical Research, Florida, USA, describes the research programme for the siRNA, olpasiran, including preclinical and Phase 1 and 2 trial data supporting its pharmacokinetic, safety and efficacy profile in targeting Lp(a).
Educational Partners and Supporters
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
(Founding Partner)